GE HealthCare Technologies (NASDAQ:GEHC) Releases Earnings Results, Beats Expectations By $0.09 EPS

GE HealthCare Technologies (NASDAQ:GEHC) announced its quarterly earnings data on Wednesday. The company reported $1.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.04 by $0.09, FiscalAI reports. GE HealthCare Technologies had a net margin of 9.10% and a return on equity of 20.46%. The firm had revenue of $5.29 billion during the quarter, compared to analyst estimates of $5.26 billion. During the same quarter in the prior year, the firm posted $1.06 earnings per share. GE HealthCare Technologies’s quarterly revenue was up 5.8% on a year-over-year basis.

Here are the key takeaways from GE HealthCare Technologies’ conference call:

• Orders rose 11.1% year over year, with a record 1.15x book-to-bill and backlog of $23.9 billion, up $2.6 billion from a year ago. Management said the strength was broad-based and not driven by one-time deals.
• Pharmaceutical Diagnostics delivered 14.6% organic revenue growth, supported by contrast media and radiopharmaceuticals. Flyrcado doses increased approximately 40% from April levels to 545 for the week ending July 24, and GE HealthCare maintained its target of at least $500 million in annual Flyrcado revenue by 2028.
• Patient Care Solutions revenue declined 13.5% and the segment reported negative EBIT due to fulfillment and supply-chain challenges. Management expects sequential improvement in the second half while reviewing strategic alternatives, including continued ownership or a potential sale.
• GE HealthCare maintained its full-year outlook of 3%–4% organic sales growth, 15.4%–15.7% adjusted EBIT margin, adjusted EPS of $4.80–$5.00, and approximately $1.6 billion in free cash flow. Second-quarter adjusted EBIT margin fell 40 basis points to 14.2% as PCS weakness and inflation offset volume growth and pricing actions.
• CFO Jay Saccaro announced his departure, with Controller and Chief Accounting Officer George Newcomb serving as interim CFO while the company begins a search for a permanent successor.

GE HealthCare Technologies Stock Up 11.0%

Shares of NASDAQ GEHC traded up $7.04 during midday trading on Wednesday, hitting $71.15. The company’s stock had a trading volume of 9,936,578 shares, compared to its average volume of 4,546,572. The company has a debt-to-equity ratio of 0.95, a current ratio of 1.22 and a quick ratio of 0.95. The firm has a market capitalization of $32.37 billion, a price-to-earnings ratio of 17.04, a price-to-earnings-growth ratio of 1.66 and a beta of 0.72. The business’s fifty day simple moving average is $63.68 and its two-hundred day simple moving average is $70.80. GE HealthCare Technologies has a 1 year low of $58.75 and a 1 year high of $89.77.

GE HealthCare Technologies Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Friday, July 24th will be given a dividend of $0.035 per share. This represents a $0.14 annualized dividend and a dividend yield of 0.2%. The ex-dividend date of this dividend is Friday, July 24th. GE HealthCare Technologies’s dividend payout ratio is currently 3.35%.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Evercore set a $80.00 price objective on GE HealthCare Technologies in a report on Thursday, April 30th. Jefferies Financial Group cut their target price on GE HealthCare Technologies from $105.00 to $90.00 in a research note on Thursday, April 30th. Royal Bank Of Canada assumed coverage on GE HealthCare Technologies in a research note on Tuesday, June 23rd. They issued an “outperform” rating and a $80.00 price target on the stock. BMO Capital Markets began coverage on GE HealthCare Technologies in a report on Wednesday, July 8th. They set a “market perform” rating and a $70.00 price target for the company. Finally, Wells Fargo & Company cut their price objective on GE HealthCare Technologies from $97.00 to $75.00 and set an “overweight” rating for the company in a research report on Thursday, April 30th. Ten research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $76.41.

Insider Activity at GE HealthCare Technologies

In related news, Director Kevin Lobo acquired 10,000 shares of the stock in a transaction dated Friday, May 22nd. The stock was acquired at an average cost of $64.18 per share, with a total value of $641,800.00. Following the completion of the transaction, the director owned 14,363 shares in the company, valued at $921,817.34. This represents a 229.20% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO James Saccaro acquired 3,310 shares of GE HealthCare Technologies stock in a transaction dated Friday, May 1st. The stock was purchased at an average price of $60.60 per share, for a total transaction of $200,586.00. Following the completion of the acquisition, the chief financial officer directly owned 87,471 shares in the company, valued at approximately $5,300,742.60. This represents a 3.93% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired 21,847 shares of company stock worth $1,361,355 over the last 90 days. 0.36% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Compound Planning Inc. boosted its position in shares of GE HealthCare Technologies by 22.6% in the 4th quarter. Compound Planning Inc. now owns 3,299 shares of the company’s stock valued at $271,000 after purchasing an additional 609 shares during the period. Invesco Ltd. grew its position in GE HealthCare Technologies by 1.6% in the 4th quarter. Invesco Ltd. now owns 7,003,172 shares of the company’s stock valued at $574,400,000 after buying an additional 112,028 shares during the last quarter. Axxcess Wealth Management LLC grew its position in GE HealthCare Technologies by 34.4% in the 4th quarter. Axxcess Wealth Management LLC now owns 3,640 shares of the company’s stock valued at $299,000 after buying an additional 931 shares during the last quarter. Corient Private Wealth LLC increased its stake in GE HealthCare Technologies by 84.7% in the 4th quarter. Corient Private Wealth LLC now owns 101,191 shares of the company’s stock valued at $8,300,000 after buying an additional 46,394 shares during the period. Finally, Ameriflex Group Inc. raised its position in GE HealthCare Technologies by 146.0% during the 4th quarter. Ameriflex Group Inc. now owns 1,358 shares of the company’s stock worth $111,000 after buying an additional 806 shares during the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Key Headlines Impacting GE HealthCare Technologies

Here are the key news stories impacting GE HealthCare Technologies this week:

• Positive Sentiment: GEHC beat earnings and revenue estimates. Adjusted earnings were $1.13 per share, above the $1.04 consensus and up from $1.06 a year earlier. Revenue rose approximately 5.7% to $5.29 billion, slightly exceeding the $5.26 billion estimate. GE HealthCare Technologies Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: Orders and backlog reached records. Orders increased 11.1%, with growth reported across every segment, while backlog climbed to $23.9 billion. The results suggest solid demand and improved visibility for future revenue. GEHC Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: Imaging demand supported profitability. Strong demand for diagnostic and imaging devices helped drive the quarterly performance. Refunds related to U.S. tariffs also benefited results. GE HealthCare Beats Quarterly Profit Estimates
• Positive Sentiment: Options activity reflected bullish positioning. Traders purchased 8,956 call options, about 45% above average call volume, indicating increased speculative interest following the earnings report.
• Neutral Sentiment: Management said Patient Care Solutions remains a focus as it works to restore growth and profitability, and the company is reviewing strategies for that business. This creates a continuing execution risk despite the strong consolidated results. GE HealthCare Reports Second Quarter 2026 Financial Results

GE HealthCare Technologies Company Profile

GE HealthCare Technologies (NASDAQ: GEHC) is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.

In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime.